Hechos relevantes

BAYER AKTIENGESELLSCHAFT

desde 01/07/1988 hasta 27/06/2024

• • 26/02/2019
  • 14:16
  • BAYER AKTIENGESELLSCHAFT
  • Information on dividends
  • Bayer proposes dividend for 2018 of 2.80 euros per share
  • Número de registro: 275140
• • 15/02/2019
  • 16:53
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
  • Número de registro: 274763
• • 15/02/2019
  • 08:14
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
  • Número de registro: 274736
• • 13/02/2019
  • 11:52
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Bayer: Calendario previsto presentación resultados Q4 2018
  • Número de registro: 274688
• • 08/01/2019
  • 17:13
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmers
  • Número de registro: 273579
• • 20/12/2018
  • 09:13
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Bayer receives approval in China for endometriosis treatment Visanne™
  • Número de registro: 272946
• • 18/12/2018
  • 13:39
  • BAYER AKTIENGESELLSCHAFT
  • Loans, credit lines and guarantees
  • Bayer extends credit line and increases volume to 4.5 billion euros
  • Número de registro: 272767
• • 05/12/2018
  • 10:11
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Bayer to drive value creation as company pursues ambitious growth targets through 2022
  • Número de registro: 272130
• • 29/11/2018
  • 15:04
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
  • Número de registro: 272007
• • 27/11/2018
  • 15:52
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Bayer receives EU approval for its hemophilia A treatment Jivi®
  • Número de registro: 271945